Cabaletta Bio Posts $51M Q2 Loss, Cash Runway to Mid-2027; Myositis Data Mid-2027
CABA has more than doubled off its 52-week low of $1.26.
Summary
Cabaletta Bio reported Q2 2026 results with a $51.0M net loss and $225.1M in cash, funding operations into mid-2027. The net loss widened as R&D costs rose. The company reiterated that registrational RESET-Myositis data is on track for mid-2027, supporting a potential BLA submission in 2H27. It also selected SSc-associated ILD as a second registrational cohort, with enrollment of approximately 25 patients anticipated to begin in 4Q26. The PC-free approach is being incorporated into RESET-MG based on emerging data from lupus and PV cohorts. ElevateBio was selected as a second CDMO for clinical and commercial manufacturing.
At the time of this announcement, CABA was trading at $2.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $464.7M. The 52-week trading range was $1.26 to $4.23. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.